These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 18052554)

  • 1. The effect of stimulant treatment for ADHD on later substance abuse and the potential for medication misuse, abuse, and diversion.
    Faraone SV; Upadhyaya HP
    J Clin Psychiatry; 2007 Nov; 68(11):e28. PubMed ID: 18052554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion.
    Faraone SV; Wilens TE
    J Clin Psychiatry; 2007; 68 Suppl 11():15-22. PubMed ID: 18307377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Managing attention-deficit/hyperactivity disorder in the presence of substance use disorder.
    Upadhyaya HP
    J Clin Psychiatry; 2007; 68 Suppl 11():23-30. PubMed ID: 18307378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of lisdexamfetamine dimesylate for the treatment of ADHD.
    Childress AC; Sallee FR
    Expert Rev Neurother; 2012 Jan; 12(1):13-26. PubMed ID: 22243042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lisdexamfetamine dimesylate: a prodrug stimulant for the treatment of ADHD in children and adults.
    Mattingly G
    CNS Spectr; 2010 May; 15(5):315-25. PubMed ID: 20448522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challenges.
    López FA; Leroux JR
    Atten Defic Hyperact Disord; 2013 Sep; 5(3):249-65. PubMed ID: 23564273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
    Najib J
    Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential for misuse and abuse of medications in ADHD: a review.
    Clemow DB; Walker DJ
    Postgrad Med; 2014 Sep; 126(5):64-81. PubMed ID: 25295651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ADHD, stimulant treatment in childhood and subsequent substance abuse in adulthood - a naturalistic long-term follow-up study.
    Dalsgaard S; Mortensen PB; Frydenberg M; Thomsen PH
    Addict Behav; 2014 Jan; 39(1):325-8. PubMed ID: 24090624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The "younger-sibling-at-risk design": a pilot study of adolescents with ADHD and an older sibling with substance use disorder.
    Donovan SJ; Levin FR
    Am J Drug Alcohol Abuse; 2011 Jul; 37(4):235-9. PubMed ID: 21517711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An update on lisdexamfetamine dimesylate for the treatment of attention deficit hyperactivity disorder.
    Wigal SB; Raja P; Shukla A
    Expert Opin Pharmacother; 2013 Jan; 14(1):137-45. PubMed ID: 23241144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substance abuse in patients with attention-deficit/hyperactivity disorder.
    Bukstein O
    Medscape J Med; 2008 Jan; 10(1):24. PubMed ID: 18324334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature.
    Wilens TE; Faraone SV; Biederman J; Gunawardene S
    Pediatrics; 2003 Jan; 111(1):179-85. PubMed ID: 12509574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lisdexamfetamine dimesylate for childhood ADHD.
    Madaan V
    Drugs Today (Barc); 2008 May; 44(5):319-24. PubMed ID: 18548134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders.
    Kollins SH
    Curr Med Res Opin; 2008 May; 24(5):1345-57. PubMed ID: 18384709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot study of stimulant medication for adults with attention-deficit/hyperactivity disorder (ADHD) who are parents of adolescents with ADHD: the acute effects of stimulant medication on observed parent-adolescent interactions.
    Babinski DE; Waxmonsky JG; Waschbusch DA; Humphrey H; Alfonso A; Crum KI; Bernstein M; Slavec J; Augustus JN; Pelham WE
    J Child Adolesc Psychopharmacol; 2014 Dec; 24(10):582-5. PubMed ID: 25386742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lisdexamfetamine.
    Blick SK; Keating GM
    Paediatr Drugs; 2007; 9(2):129-35; discussion 136-8. PubMed ID: 17407369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lisdexamfetamine dimesylate: the first long-acting prodrug stimulant treatment for attention deficit/hyperactivity disorder.
    Faraone SV
    Expert Opin Pharmacother; 2008 Jun; 9(9):1565-74. PubMed ID: 18518785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lisdexamfetamine: a prodrug for the treatment of attention-deficit/hyperactivity disorder.
    Popovic B; Bhattacharya P; Sivaswamy L
    Am J Health Syst Pharm; 2009 Nov; 66(22):2005-12. PubMed ID: 19890083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
    Roskell NS; Setyawan J; Zimovetz EA; Hodgkins P
    Curr Med Res Opin; 2014 Aug; 30(8):1673-85. PubMed ID: 24627974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.